The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635

PARSIPPANY, NJ, Jun 30 (MARKET WIRE) --
The Medicines Company (NASDAQ: MDCO) announced today that in accordance
with NASDAQ Marketplace Rule 5635, the Company issued new inducement
stock options to one new hire due to additional hiring in connection with
its global expansion.

The inducement stock options covers 1,000 shares of common stock and are
classified as non-qualified stock options with an exercise price equal to
the fair market value on the grant date. The options have a 10-year term
and vest over four years as follows: 25 percent of these options will vest
on the date one year from the optionee's hire date, the remainder will
vest in monthly increments during the following 36 months (in all cases
subject to the terms and conditions of the Company's 2009 Equity
Inducement Plan).

About The Medicines Company

The Medicines Company (NASDAQ: MDCO) is focused on advancing the treatment
of critical care patients through the delivery of innovative,
cost-effective medicines to the worldwide hospital marketplace. The
Company markets Angiomax(R) (bivalirudin) in the United States and other
countries for use in patients undergoing coronary angioplasty, and
Cleviprex(R) (clevidipine butyrate) injectable emulsion in the United
States for the reduction of blood pressure when oral therapy is not
feasible or not desirable. The Company also has two products in late
stage development, cangrelor, an investigational antiplatelet agent and
oritavancin, a semi-synthetic lipoglycopeptide antibiotic currently
awaiting EU regulatory approval. The Company's pipeline also includes a
serine protease inhibitor, CU2010, in early-stage development. The
Medicines Company's website is www.themedicinescompany.com.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this press release about The Medicines Company
that are not purely historical, and all other statements that are not
purely historical, may be deemed to be forward-looking statements for
purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995. Without limiting the foregoing, the words
"believes," "anticipates," "expects" and "estimates" and similar
expressions are intended to identify forward-looking statements. These
forward-looking statements involve known and unknown risks and
uncertainties that may cause the Company's actual results, levels of
activity, performance or achievements to be materially different from
those expressed or implied by these forward-looking statements. Important
factors that may cause or contribute to such differences include: whether
the Company will be able to obtain regulatory approvals; whether the
Company's products and product candidates will advance in the clinical
trial process on a timely basis or at all; whether clinical trial results
will warrant submission of applications for regulatory approval; whether
physicians, patients and other key decision-makers will accept clinical
trial results; whether the Company will be able to successfully
distribute and market its approved products; and such other factors as
are set forth in the risk factors detailed from time to time in the
Company's periodic reports and registration statements filed with the
Securities and Exchange Commission including, without limitation, the
risk factors detailed in the Company's Annual Report on Form 10-Q filed
on May 11, 2009, which are incorporated herein by reference. The Company
specifically disclaims any obligation to update these forward-looking
statements.

Copyright 2009, Market Wire, All rights reserved.

-0-